HomeCompareAMYT vs SBUX

AMYT vs SBUX: Dividend Comparison 2026

AMYT yields 13.61% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $118.1K in total portfolio value· pulled ahead in Year 7
10 years
AMYT
AMYT
● Live price
13.61%
Share price
$14.70
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.9K
Annual income
$3,165.25
Full AMYT calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — AMYT vs SBUX

📍 SBUX pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMYTSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMYT + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMYT pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMYT
Annual income on $10K today (after 15% tax)
$1,156.46/yr
After 10yr DRIP, annual income (after tax)
$2,690.46/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $57,775.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMYT + SBUX for your $10,000?

AMYT: 50%SBUX: 50%
100% SBUX50/50100% AMYT
Portfolio after 10yr
$108.0K
Annual income
$37,150.86/yr
Blended yield
34.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

AMYT
Analyst Ratings
5
Hold
Consensus: Hold
Price Target
$14.50
-1.4% upside vs current
Range: $14.50 — $14.50
Altman Z
0.0
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMYT buys
0
SBUX buys
0
No recent congressional trades found for AMYT or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMYTSBUX
Forward yield13.61%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$48.9K$167.0K
Annual income after 10y$3,165.25$71,136.45
Total dividends collected$22.3K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy
Analyst price target$14.50$104.00

Year-by-year: AMYT vs SBUX ($10,000, DRIP)

YearAMYT PortfolioAMYT Income/yrSBUX PortfolioSBUX Income/yrGap
1$12,061$1,360.54$11,121$420.68+$940.00AMYT
2$14,438$1,533.54$12,548$648.40+$1.9KAMYT
3$17,165$1,715.78$14,440$1,013.98+$2.7KAMYT
4$20,273$1,906.34$17,068$1,617.30+$3.2KAMYT
5$23,796$2,104.21$20,912$2,649.52+$2.9KAMYT
6$27,770$2,308.32$26,875$4,499.29+$895.00AMYT
7← crossover$32,231$2,517.59$36,771$8,014.12$4.5KSBUX
8$37,219$2,730.91$54,542$15,197.11$17.3KSBUX
9$42,771$2,947.15$89,602$31,242.49$46.8KSBUX
10$48,930$3,165.25$167,011$71,136.45$118.1KSBUX

AMYT vs SBUX: Complete Analysis 2026

AMYTStock

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Full AMYT Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this AMYT vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMYT vs SCHDAMYT vs JEPIAMYT vs OAMYT vs KOAMYT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.